Trial Profile

A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glembatumumab vedotin (Primary)
Indications Advanced breast cancer
Focus Therapeutic Use
Acronyms EMERGE
Sponsors Celldex Therapeutics Inc

Most Recent Events

27 Sep 2015 Results of post-hoc analysis (n=328) presented at the ASCO - Breast Cancer Symposium 2015
06 Apr 2015 According to a Celldex Therapeutics media release, the data from this study supported the initiation of the phase 2 METRIC study. (See CT profile 700239414)
06 Apr 2015 Results published in a Celldex Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com